Why has immune "checkpoint" therapy failed in most clinical trials?

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Cancer immunotherapy utilizing PD-1/PD-L1 pathway blockade has achieved significant clinical success in various cancers.
• Development of other immune checkpoint inhibitors targeting molecules such as TIM-3 and TIGIT has yielded limited clinical benefits, even in combination therapies.

Purpose of the Study:

• To explore key hypotheses explaining the differential therapeutic success of immune checkpoint inhibitors.
• To provide a biologically informed strategy for advancing cancer immunotherapy.

Main Methods:

• Review of select evidence and scientific literature.
• Exploration of three core hypotheses regarding checkpoint inhibitor efficacy.
• Analysis of tumor microenvironment (TME) immune evasion mechanisms.

Main Results:

• Hypothesis 1: Many checkpoint targets lack tumor-specific immunosuppressive functions.
• Hypothesis 2: Immune evasion mechanisms in the TME are dominant but not redundant.
• Hypothesis 3: Acquired resistance emerges during therapy.

Conclusions:

• The limited success of novel checkpoint inhibitors may stem from their targets' biology and the complex TME.
• A more strategic approach, considering tumor-specific immunosuppression, TME dynamics, and resistance mechanisms, is crucial for future cancer immunotherapy development.